NCT04521686 2026-04-22Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting200 enrolled
NCT05786924 2026-04-21Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesServierPhase 1/2 Recruiting554 enrolled